SuperworthBioNexus Gene Lab price to free cash flow BGLC
Market value divided by free cash flow over the last twelve months, since 2022.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 21.2×
- Mar 2024
- Peer median
- 9.5×
BioNexus Gene Lab's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in Mar 2024, at 21.2×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2024 | 21.2× | 12.4× | 30.1× |
| 2023 | 15.5× | 9.6× | 425× |
| 2022 | 321× | 243× | 366× |
Against its peers
Companies in Healthcare nearest BioNexus Gene Lab's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| BGLCBioNexus Gene Lab | n/m |
| OXBROXBRIDGE RE HOLDINGS | n/m |
| EDUCEducational Development | 49.2× |
| GTIMGood Times Restaurants | 5.2× |
| MDRRMedalist Diversified | n/m |
| BCGBinah Capital | 3.2× |
| VIPVulcan Infrastructure & Power | n/m |
| MXCMexco Energy | 13.7× |
| CKXCKX Lands | n/m |
| MSGMMotorsport Games | n/m |
| ATCHAtlasClear | n/m |
| Peer median | 9.5× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on BioNexus Gene Lab
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.